Carly Oboudiyat1, Tamar Gefen2, Eleni Varelas2, Sandra Weintraub2, Emily Rogalski2, Eileen H Bigio2, M-Marsel Mesulam2. 1. Cognitive Neurology and Alzheimer's Disease Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Electronic address: c.oboudiyat@gmail.com. 2. Cognitive Neurology and Alzheimer's Disease Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Abstract
INTRODUCTION: The accuracy of cerebrospinal fluid (CSF) biomarkers for detecting Alzheimer's disease (AD) pathology has not been fully validated in autopsied nonamnestic dementias. METHODS: We retrospectively evaluated CSF amyloid β 1-42, phosphorylated-tau, and amyloid-tau index as predictors of Alzheimer pathology in patients with primary progressive aphasia, frontotemporal dementia, and progressive supranuclear palsy. RESULTS: Nineteen nonamnestic autopsied cases with relevant CSF values were included. At autopsy, nine had AD and 10 had non-AD pathologies. All six patients whose combined CSF phosphorylated-tau and amyloid β levels were "consistent with AD" had postmortem Alzheimer pathology. The two patients whose biomarker values were "not consistent with AD" had non-AD pathologies. The CSF values of the remaining eight non-AD cases were in conflicting or borderline ranges. DISCUSSION: CSF biomarkers reliably identified Alzheimer pathology in nonamnestic dementias and may be useful as a screening measure for inclusion of nonamnestic cases into Alzheimer's trials.
INTRODUCTION: The accuracy of cerebrospinal fluid (CSF) biomarkers for detecting Alzheimer's disease (AD) pathology has not been fully validated in autopsied nonamnestic dementias. METHODS: We retrospectively evaluated CSF amyloid β 1-42, phosphorylated-tau, and amyloid-tau index as predictors of Alzheimer pathology in patients with primary progressive aphasia, frontotemporal dementia, and progressive supranuclear palsy. RESULTS: Nineteen nonamnestic autopsied cases with relevant CSF values were included. At autopsy, nine had AD and 10 had non-AD pathologies. All six patients whose combined CSF phosphorylated-tau and amyloid β levels were "consistent with AD" had postmortem Alzheimer pathology. The two patients whose biomarker values were "not consistent with AD" had non-AD pathologies. The CSF values of the remaining eight non-AD cases were in conflicting or borderline ranges. DISCUSSION: CSF biomarkers reliably identified Alzheimer pathology in nonamnestic dementias and may be useful as a screening measure for inclusion of nonamnestic cases into Alzheimer's trials.
Authors: Thomas J Montine; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; John Q Trojanowski; Harry V Vinters; Bradley T Hyman Journal: Acta Neuropathol Date: 2011-11-20 Impact factor: 17.088
Authors: Jon B Toledo; Johannes Brettschneider; Murray Grossman; Steven E Arnold; William T Hu; Sharon X Xie; Virginia M-Y Lee; Leslie M Shaw; John Q Trojanowski Journal: Acta Neuropathol Date: 2012-04-22 Impact factor: 17.088
Authors: Christopher M Clark; Sharon Xie; Jesse Chittams; Douglas Ewbank; Elaine Peskind; Douglas Galasko; John C Morris; Daniel W McKeel; Martin Farlow; Sharon L Weitlauf; Joseph Quinn; Jeffrey Kaye; David Knopman; Hiroyuki Arai; Rachelle S Doody; Charles DeCarli; Susan Leight; Virginia M-Y Lee; John Q Trojanowski Journal: Arch Neurol Date: 2003-12
Authors: Emily Joy Rogalski; Jaiashre Sridhar; Adam Martersteck; Benjamin Rader; Derin Cobia; Anupa K Arora; Angela J Fought; Eileen H Bigio; Sandra Weintraub; Marek-Marsel Mesulam; Alfred Rademaker Journal: Alzheimers Dement Date: 2019-02-11 Impact factor: 21.566
Authors: Jonathan Graff-Radford; Keir X X Yong; Liana G Apostolova; Femke H Bouwman; Maria Carrillo; Bradford C Dickerson; Gil D Rabinovici; Jonathan M Schott; David T Jones; Melissa E Murray Journal: Lancet Neurol Date: 2021-03 Impact factor: 44.182